- RecruitingPHASE3
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
This study looks at adding a new medicine, navtemadlin, to an existing treatment, ruxolitinib, for people with myelofibrosis. It aims to see if this combination works better for those whose myelofibrosis isn't fully controlled by ruxolitinib alone.
For: Myelofibrosis · Post-PV MF · Post-ET MyelofibrosisUnited States · Australia · Austria - Active not recruitingPHASE3
A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis
This study is testing a new cream called Ruxolitinib for children and teenagers aged 6 to 17 who have moderate eczema (atopic dermatitis). We want to see if it's safe and effective at reducing their skin symptoms. There's also a 'dummy' cream for comparison.
For: Atopic DermatitisUnited States · Belgium · Canada - Active not recruitingPHASE1
Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms
This study looks at a new drug, INCB057643, for people with certain blood cancers like myelofibrosis. It checks if the drug is safe, what dose works best, and if it helps by itself or when given with another medicine called ruxolitinib.
For: Myelofibrosis · Myelodysplastic Syndrome · Myelodysplastic/Myeloproliferative Neoplasm Overlap SyndromeUnited States · Canada · China - RecruitingPHASE1, PHASE2
Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib
This study is looking into a new drug, TL-895, for myelofibrosis, a bone marrow disorder. It’s for people who haven't tried a common treatment called ruxolitinib yet, or those who aren't getting enough benefit from ruxolitinib alone.
For: Myelofibrosis · Primary Myelofibrosis · Post-PV MFUnited States · France · Germany - RecruitingPHASE1, PHASE2
HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
This study looks at new treatments for children and young adults with specific types of blood cancer that have come back or not responded to previous treatment. It tests a combination of medicines to see if they are safe and work well for those whose cancer has certain genetic changes.
For: Acute Lymphoblastic Leukemia, in Relapse · Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent · Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) RecurrentAustria · Belgium · Denmark - Active not recruitingPHASE1
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
This study looks at a new drug, INCA033989, alone or with ruxolitinib, for blood cancers called myeloproliferative neoplasms. Researchers want to find a safe and effective dose, checking for side effects and how well patients can tolerate the treatment.
For: Myeloproliferative NeoplasmsAustralia · Canada · Denmark - Active not recruitingPHASE4
CINC424A2X01B Rollover Protocol
This study is for patients already taking ruxolitinib, or ruxolitinib with panobinostat, in a previous trial, and who are still benefiting. It lets them continue their treatment and helps researchers learn more about the long-term safety of these medications.
For: Primary Myelofibrosis · Polycythemia Vera · Graft Versus Host DiseaseAustralia · Belgium · Bulgaria - Not yet recruitingPHASE2, PHASE3
Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL
This study looks at new ways to make stem cell transplants safer and more effective for children and young people with a type of blood cancer called ALL. Researchers want to reduce serious side effects and improve long-term health for these patients.
For: Acute Lymphoblastic Leukemia (ALL) · Stem Cell Transplant · Graft -Versus-host-diseaseAustria · Czechia · Denmark - Active not recruitingPHASE3
A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)
This study looks at a new drug, bomedemstat, for essential thrombocythemia (ET). It compares bomedemstat to standard treatments for people whose current medicine, hydroxyurea, isn't working well or causes too many side effects. We want to see if bomedemstat is safer and works better.
For: Essential ThrombocythemiaUnited States · Argentina · Australia - Active not recruitingPHASE3
Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis
This study is looking at a new combination treatment for myelofibrosis, a blood disorder. It combines a drug called Selinexor with Ruxolitinib to see if it's safe and helps people who haven't tried other similar treatments for myelofibrosis before.
For: MyelofibrosisUnited States · Australia · Belgium - Active not recruitingPHASE3
Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
This study is testing a new medicine called pelabresib alongside an existing treatment (ruxolitinib) for adults with myelofibrosis who haven't tried similar drugs before. It aims to see if this combination works better than ruxolitinib alone to help manage symptoms and spleen size.
For: Myelofibrosis · Primary Myelofibrosis · Post-polycythemia Vera MyelofibrosisUnited States · Australia · Austria - RecruitingPHASE1, PHASE2
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
This study is testing a new medicine, nuvisertib, for myelofibrosis. It aims to see if it's safe and how it works, either alone or with ruxolitinib. It's for people whose current treatments aren’t working well.
For: MyelofibrosisUnited States · Australia · Belgium - RecruitingPHASE3
MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera
This study compares a new drug, ruxolitinib, with standard treatments (hydroxycarbamide or interferon) for people with high-risk Polycythaemia Vera. It aims to see which treatment works best as a first approach.
For: Polycythemia VeraUnited Kingdom - RecruitingPHASE2
A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
This study looks at a new drug, selinexor, for people with a bone marrow condition called myelofibrosis. It's for those who haven't tried certain other treatments and have low to normal platelet counts. The main aim is to see if selinexor can shrink an enlarged spleen.
For: Myelofibrosis · Moderate Thrombocytopenia · Mild ThrombocytopeniaUnited States · Belgium · Bulgaria - RecruitingPHASE2
A Study of Elritercept Alone or Together With Ruxolitinib in Adults With Myelofibrosis
This study looks at a new medicine called Elritercept for myelofibrosis, a bone marrow condition. Researchers want to see if it's safe and effective when used alone or with another medicine called Ruxolitinib. They're also checking how it affects symptoms and red blood cell counts.
For: MyelofibrosisAustralia · Brazil · France - Active not recruitingPHASE2
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease
This study looks at a new drug, axatilimab, combined with an existing one, ruxolitinib, to treat a condition called chronic graft-versus-host disease (cGVHD). It aims to see how safe and effective this new combination is.
For: Chronic Graft-versus-host-diseaseUnited States · Belgium · Canada - Active not recruitingPHASE1, PHASE2
INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders
This study looks at a new drug, INCB000928, by itself or with ruxolitinib, for people with myelofibrosis who have anaemia (low red blood cells) and need blood transfusions, or have anaemia symptoms. It aims to find a safe and effective dose.
For: Anemia · Post-essential Thrombocythemia Myelofibrosis · Post-polycythemia Vera MyelofibrosisUnited States · Canada · France - Active not recruitingPHASE1
A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm
This study looks at a new drug, navitoclax, alone or with an existing drug, ruxolitinib, for a group of blood cancers called myeloproliferative neoplasms. Researchers want to see if it's safe, how the body handles it, and if it affects other drugs.
For: Myeloproliferative NeoplasmUnited States · Belgium · Bulgaria - Active not recruitingPHASE3
Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis
This study looks at a new drug, navitoclax, combined with ruxolitinib, or navitoclax alone, for adults with myelofibrosis whose previous treatment didn't work. It compares these to standard care to see how they affect spleen size and safety.
For: Myelofibrosis (MF)United States · Australia · Austria - RecruitingPHASE1
A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms
This study is testing a new medicine, JNJ-88549968, for people with specific types of blood cancers called myeloproliferative neoplasms (MPNs) that have a CALR gene mutation. It aims to find the safest dose and see how well it works, sometimes given with other existing treatments.
For: NeoplasmsUnited States · Canada · China - Active not recruitingPHASE1
A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers
This study is testing a new medicine, IOA-244, for people with certain advanced cancers, including lymphoma and melanoma. It aims to see if the medicine is safe and if it can help the body's immune system fight cancer, both alone and with other treatments.
For: Solid Tumor, Adult · Non-Hodgkin Lymphoma, Adult · NSCLCItaly · United Kingdom - Active not recruitingPHASE1, PHASE2
A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)
This study looks at a new drug, BMS-986158, alone or with other medicines like Ruxolitinib or Fedratinib, for a type of blood cancer called myelofibrosis. Researchers want to see if these treatments are safe and how well they work.
For: MyelofibrosisUnited States · Australia · France